PCI Complexity Influences Optimal Duration of DAPT

Share this content:
PCI Complexity Influences Optimal Duration of DAPT
PCI Complexity Influences Optimal Duration of DAPT

MONDAY, Aug. 29, 2016 (HealthDay News) -- The safety of dual antiplatelet therapy (DAPT) duration varies with percutaneous coronary intervention (PCI) complexity, according to research published online Aug. 29 in the Journal of the American College of Cardiology. The research was published to coincide with the annual European Society of Cardiology Congress, held from Aug. 27 to 31 in Rome.

Gennaro Giustino, M.D., from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues pooled data from six randomized controlled trials examining DAPT durations after PCI. Data were included for 9,577 patients for whom procedural variables were available, of whom 17.5 percent underwent complex PCI.

The researchers found that patients who underwent complex PCI had a higher risk of major adverse cardiovascular events (MACE) at a median follow-up of 392 days (adjusted hazard ratio, 1.98; 95 percent confidence interval, 1.50 to 2.60). Significant reductions in MACE were seen for long-term versus short-term DAPT in the complex PCI group (adjusted hazard ratio, 0.56; 95 percent confidence interval, 0.35 to 0.89) versus noncomplex PCI (adjusted hazard ratio, 1.01; 95 percent confidence interval, 0.75 to 1.35). For long-term DAPT, the magnitude of the benefit was progressively greater per increase in procedural complexity. Long-term DAPT was associated with elevated bleeding risk, which was equivalent between the groups.

"Alongside other established clinical risk factors, procedural complexity is an important parameter to take into account in tailoring upfront duration of DAPT," the authors write.

Several authors disclosed financial ties to the pharmaceutical and medical device industries; Medtronic provided the data for the OPTIMIZE trial.

Full Text (subscription or payment may be required)
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »